Barclays’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.88M Sell
106,734
-78,943
-43% -$3.53M ﹤0.01% 1975
2025
Q4
$8.64M Buy
185,677
+2,441
+1% +$109K ﹤0.01% 1786
2025
Q3
$7.63M Sell
183,236
-108,811
-37% -$3.48M ﹤0.01% 1872
2025
Q2
$8.4M Buy
292,047
+126,136
+76% +$3.9M ﹤0.01% 1695
2025
Q1
$5.56M Sell
165,911
-16,030
-9% -$599K ﹤0.01% 1825
2024
Q4
$9.3M Sell
181,941
-25,771
-12% -$1.44M ﹤0.01% 1624
2024
Q3
$10.6M Buy
207,712
+89,358
+76% +$4.61M ﹤0.01% 1447
2024
Q2
$5.3M Buy
118,354
+43,459
+58% +$2.01M ﹤0.01% 1494
2024
Q1
$3.51M Sell
74,895
-116,089
-61% -$4.54M ﹤0.01% 2095
2023
Q4
$6.8M Buy
190,984
+77,702
+69% +$2.38M ﹤0.01% 1842
2023
Q3
$3.37M Buy
113,282
+21,189
+23% +$437K ﹤0.01% 1571
2023
Q2
$1.66M Sell
92,093
-17,180
-16% -$343K ﹤0.01% 2004
2023
Q1
$1.75M Buy
109,273
+40,430
+59% +$748K ﹤0.01% 2289
2022
Q4
$1.26M Buy
68,843
+18,238
+36% +$321K ﹤0.01% 2622
2022
Q3
$994K Buy
50,605
+46,563
+1,152% +$950K ﹤0.01% 2238
2022
Q2
$75K Sell
4,042
-5,444
-57% -$109K ﹤0.01% 3888
2022
Q1
$208K Sell
9,486
-48,301
-84% -$978K ﹤0.01% 3411
2021
Q4
$1.64M Buy
57,787
+40,652
+237% +$1M ﹤0.01% 2501
2021
Q3
$361K Buy
17,135
+2,074
+14% +$43.4K ﹤0.01% 3342
2021
Q2
$283K Sell
15,061
-9,521
-39% -$167K ﹤0.01% 3390
2021
Q1
$375K Buy
24,582
+13,674
+125% +$212K ﹤0.01% 3359
2020
Q4
$153K Sell
10,908
-3,333
-23% -$46.4K ﹤0.01% 3919
2020
Q3
$223K Sell
14,241
-2,547
-15% -$38.9K ﹤0.01% 3777
2020
Q2
$295K Buy
16,788
+13,128
+359% +$224K ﹤0.01% 3766
2020
Q1
$54K Sell
3,660
-7,538
-67% -$154K ﹤0.01% 5183
2019
Q4
$281K Buy
11,198
+5,215
+87% +$99.3K ﹤0.01% 4773
2019
Q3
$90K Sell
5,983
-2,650
-31% -$51.5K ﹤0.01% 5551
2019
Q2
$216K Buy
8,633
+3,311
+62% +$82K ﹤0.01% 5033
2019
Q1
$121K Buy
+5,322
New +$131K ﹤0.01% 5209
2018
Q4
Sell
-2,608
Closed -$75K 6987
2018
Q3
$75K Buy
+2,608
New +$77.4K ﹤0.01% 5797

Other funds holding CRNX